20 May 2013
Keywords: Canada, EU trade agreement, CETA, CGPA, Rx&D, Intellectual property
Article | 12 October 2011
Canada could face a loss of jobs and investment in its R&D intensive and fast-growing generic pharmaceutical industry ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
12 October 2011
11 October 2011
17 May 2013
© 2013 thepharmaletter.com